James M Pellissier

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings
    J M Pellissier
    Merck Research Laboratories, Blue Bell, PA 19422, USA
    Am J Manag Care 6:1038-44. 2000
  2. ncbi request reprint Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis
    J M Pellissier
    Clinical and Health Economic Statistics, Merck Research Laboratories, Blue Bell, PA 19422, USA
    Clin Ther 23:1061-79. 2001
  3. ncbi request reprint Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
    James M Pellissier
    Merck Research Laboratories, Blue Bell, PA, United States
    Vaccine 25:8326-37. 2007
  4. ncbi request reprint Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Pharmacoeconomics 25:155-69. 2007
  5. doi request reprint Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans
    Ronald R White
    Department of Global Outcomes Research, Global Human Health, West Point, Pennsylvania, USA
    Pharmacoeconomics 27:781-92. 2009
  6. pmc The incidence of herpes zoster in a United States administrative database
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, Blue Bell, PA, USA
    J Gen Intern Med 20:748-53. 2005
  7. ncbi request reprint Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritis
    James M Pellissier
    Ann Intern Med 140:761; author reply 761-2. 2004
  8. ncbi request reprint An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis
    Thomas J Schnitzer
    Northwestern Center for Clinical Research, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    Clin Ther 25:3162-72. 2003
  9. ncbi request reprint Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia
    Marc Brisson
    Clin Infect Dis 45:1527-9. 2007
  10. doi request reprint Comparative costs of ertapenem and cefotetan as prophylaxis for elective colorectal surgery
    Samuel E Wilson
    Department of Surgery, University of California, Irvine, Orange, California, USA
    Surg Infect (Larchmt) 9:349-56. 2008

Collaborators

Detail Information

Publications10

  1. ncbi request reprint The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings
    J M Pellissier
    Merck Research Laboratories, Blue Bell, PA 19422, USA
    Am J Manag Care 6:1038-44. 2000
    ..Fewer injections benefit the patient/child and the parent/caregiver, and the healthcare provider may benefit from savings in personnel time associated with vaccine administration. To date, however, these savings have not been quantified...
  2. ncbi request reprint Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis
    J M Pellissier
    Clinical and Health Economic Statistics, Merck Research Laboratories, Blue Bell, PA 19422, USA
    Clin Ther 23:1061-79. 2001
    ....
  3. ncbi request reprint Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
    James M Pellissier
    Merck Research Laboratories, Blue Bell, PA, United States
    Vaccine 25:8326-37. 2007
    ..s.)...
  4. ncbi request reprint Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, North Wales, Pennsylvania 19454 1099, USA
    Pharmacoeconomics 25:155-69. 2007
    ..Although there are estimated to be nearly 1 million cases of herpes zoster diagnosed in the US each year, the economic costs associated with herpes zoster in the US have not been well described...
  5. doi request reprint Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans
    Ronald R White
    Department of Global Outcomes Research, Global Human Health, West Point, Pennsylvania, USA
    Pharmacoeconomics 27:781-92. 2009
    ..The majority of medical RU and cost burden is incurred by the elderly. Although many people with HZ may no longer be in the workforce, HZ does contribute to lost work time...
  6. pmc The incidence of herpes zoster in a United States administrative database
    Ralph P Insinga
    Department of Health Economic Statistics, Merck Research Laboratories, Blue Bell, PA, USA
    J Gen Intern Med 20:748-53. 2005
    ..Few recent studies have reported data on the incidence of herpes zoster (HZ) in U.S. general clinical practice...
  7. ncbi request reprint Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritis
    James M Pellissier
    Ann Intern Med 140:761; author reply 761-2. 2004
  8. ncbi request reprint An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis
    Thomas J Schnitzer
    Northwestern Center for Clinical Research, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
    Clin Ther 25:3162-72. 2003
    ..This study assessed prescribing patterns for rofecoxib and celecoxib in the treatment of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as differences in prescribing patterns across physician specialties...
  9. ncbi request reprint Cost-effectiveness of herpes zoster vaccine: flawed assumptions regarding efficacy against postherpetic neuralgia
    Marc Brisson
    Clin Infect Dis 45:1527-9. 2007
  10. doi request reprint Comparative costs of ertapenem and cefotetan as prophylaxis for elective colorectal surgery
    Samuel E Wilson
    Department of Surgery, University of California, Irvine, Orange, California, USA
    Surg Infect (Larchmt) 9:349-56. 2008
    ..This project was intended to determine the potential cost impact of using ertapenem 1 g vs. cefotetan 2 g as prophylaxis for elective colorectal surgery...